Chinese RNA-based medicine developer Suzhou Ribo Life Science has filed a Hong Kong IPO, aiming to raise new funds for its lead RBD4059 drug candidate for thrombotic diseases. The small-interfering ...
A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared for phase 3 trials in asthma – even though it missed the mark in a midstage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results